3种新型血管扩张剂治疗急性脑梗死的最小成本分析

Cost-minimization Analysis of three New Vasodilators in Treating Acute Cerebral Infarction

目的比较长春西汀(丁那)、丁咯地尔(瑞立达)及马来酸桂哌齐特(克林澳)分别联合奥扎格雷钠(丹奥)治疗急性脑梗死(ACI)的效果和成本。方法运用药物经济学最小成本分析法从患者的角度出发对治疗的效果及成本进行分析。结果3种方案的总有效率为82.14%、81.48%、87.10%。差异无统计学意义(P>0.05)。人均治疗总成本分别为5263.53±679.30元、4826.36±606.65元、6341.25±701.33元。差异有统计学意义(P<0.001)。主药成本分别为2788.80元、2612.40元和3309.60元。结论马来酸桂哌齐特联合奥扎格雷钠治疗急性脑梗死为最佳方案。

OBJECTIVE To compare the effects and costs of three new vasodilators （vinpocetine; buflomedil; cinepazide） combined with ozagrel in treating acute cerebral infarction （ACI）. METHODS Cost-minimization analysis （CMA） of pharmacoeconomics was applied to analyze the therapeutic effects and costs from the point of patients. RESULTS The effective rates of three regiments were 82. 14%, 81.48% and 87. 10% , respectively. There was no significant difference in effects of the three therapeutic regiments. The total treatment cost per capita in three groups was 5263.53±679.30 yuan,4826.36 ± 606.65 yuan and 6341.25 ±701.33 yuan,respectively,and there was significant difference. The main drug cost was 2788.80 yuan,2612.40 yuan and 3309.60 yuan, respectively. CONCLUSION Cinepazide is the perfect regimen of three new vasodilators combined with ozagrel in treating ACI.